Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07211659 · ClinicalTrials.gov registry record · Phase 1
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
A Phase 1 study of Ovarian Cancer, sponsored by Theolytics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT07211659 is a Phase 1 study of Ovarian Cancer that is actively recruiting participants, run by Theolytics Limited. The registered enrollment target is 18 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07211659, a Phase 1 study of Ovarian Cancer, is actively recruiting participants, sponsored by Theolytics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will also aim to establish if THEO-260 is able to treat ovarian cancer. The main questions it aims to answer are: * What medical problems do participants have when taking THEO-260? * At what dose is THEO-260 both safe but also shows signs of being able to treat ovarian cancer? The clinical trial follows a dose escalation/ finding design where we will aim to establish a Recommended Phase 2 Dose (RP2D). Participants will: * Be administered 6 doses of THEO-260 via an intraperitoneal (IP) route of administration over the course of 2 weeks. * They will then visit the clinic at regular intervals for check-ups and tests to monitor safety and THEO-260 ability to treat ovarian cancer.
Conditions Studied
Interventions
- BIOLOGICAL THEO-260
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-02-28 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07211659
The ClinicalTrials.gov registry entry for NCT07211659 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Theolytics Limited, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which THEO-260 is the first listed.
NCT07211659 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07211659 about?
NCT07211659 is a clinical study titled "Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients". The goal of this clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will also aim to establish if THEO-260 is able to treat ovarian cancer. The main questions it aims to answer are: * What medical problems do participants have when taking THEO-...
What is the current status of trial NCT07211659?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-02-28. Estimated completion is 2027-12.
What conditions does trial NCT07211659 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT07211659?
The interventions under investigation include: THEO-260 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07211659?
This trial is sponsored by Theolytics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07211659 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.